Bradley Arant Boult Cummings RFP

31 / 138

PAGE 3 0
Brokerage Services for Insurance and Employee Benefits
strategic consulting services including, but not limited to:
 Carrier or PBM pharmacy contract review – Carve-in and Carve-out
 Pharmacy Benefit Manager marketing (procurement)
 Plan design and benefit management
 Implementation oversight
 Market check (as allowed in current contract)
 Annual pharmacy experience review and clinical recommendations
 Vendor management
 Retiree specific drug strategies including Employer Group Waiver Plan (EGWP) and Retiree Drug Subsidy
(RDS) support
 Ad-hoc projects (e.g. onsite pharmacy, 340B optimization, etc.)
The CBIZ pharmacy practice consults with clients to review past pharmacy experience and provide strategic
recommendations pursuant to their specific needs and corporate culture while also providing guidance around best
practices for pharmacy management.
The National Pharmacy Practice is led by Michael Zucarelli, PharmD who is a licensed and practicing pharmacist.
The practice offers our clients a breadth of pharmacy expertise ranging from marketplace perspectives, vendor
capabilities as well as valuable practical and clinical knowledge. The pharmacy team will collaborate with the local
consultants and actuarial teams to provide pharmacy specific guidance as it pertains to health care reform, industry
trends and the specific objectives of each client. The team will work with current or prospective pharmacy benefit
managers to maximize the value of each dollar spent on pharmacy.
This includes:
 Achieving the best price through contract renewals and performance guarantees
 Ensuring the safe and appropriate use of medications through clinical recommendations
 Working with vendors to optimize distribution channels including site of care
 Collaborate with vendors to ensure adequate reporting of pharmacy expenditures
 Ensuring medical, disease management, and PBM vendors are accountable for medication adherence and
outcomes
 Aligning strategies to prepare for impactful drug launches or guideline changes and clinical
recommendations to mitigate upward trend pressures
 Meeting the needs of State and Federal regulations including provisions of health care reform